Investor Presentation
New and Emerging Markets
2020 Revenue:
% of 2020 Revenue:
2021e Revenue:
2021e Incremental:
% of 2021 Revenue:
Franchise Tailwinds:
Where our Products Play:
Healthy
Biologics
Pipeline to Fuel
Future Growth:
mAbs¹
COVID-19 Vaccines & Therapeutics
$46M
13%
$175 - $180M (from $46M in 2020)
$129 - $134M
~27%
Filtration, Chromatography, Proteins
Viral vector vaccines rProteins
mRNA
>120
FDA
approved
YE 2020
>630
clinical trials
Therapeutic mAbs
3
FDA EUA
approved
YE 2020
>1,500
clinical trials
1. Antibodies to Watch in 2020; MAbs. 2020 Jan-Dec; 12(1): 170353
2. Alliance for Regenerative Medicine Q3 2020 report https://alliancerm.org/sector-report/q3-2020-trend-talk/Deloitte report with references GT CAGR
Gene and Cell Therapy
R REPLIGEN
INSPIRING ADVANCES IN BIOPROCESSING
$54M
15% (+30% year-on-year growth)
$71 - $76M (+30% -40% year-on year growth)
$16 - $22M
~11%
Filtration, Chromatography, Process Analytics
Plasmids
AAV
Lentivirus
mRNA
9
FDA
approved
YE 2020
>1,000
clinical trials²
8View entire presentation